26
Aug
It’s been a year of anticipation for Lykos Therapeutics, as they await a landmark decision from the Food and Drug Administration (FDA). The drugmaker had filed an application to approve MDMA as a treatment for PTSD, expecting a positive outcome that would catapult them to new heights. However, on August 9, the FDA responded with a rebuttal, culminating growing concerns about the quality of Lykos’ clinical trials. Following the decision, the journal Psychopharmacology retracted three studies related to MDMA research, citing unethical practices and making serious allegations, including sexual misconduct by an unlicensed therapist at one of the study sites.…